Dr. Dominik Schumacher
CEO Tubulis

Topic: Our path to pharma partnership: positioning Tubulis in the highly competitive ADC market
Tubulis entered into a strategic partnership with Bristol Myers Squibb in April 2023 to develop next-generation ADCs in oncology. The deal includes an upfront payment of $22.75 million to Tubulis and milestone payments of more than $1 billion.

Prof. Julian Grünewald
TUM

Topic: CRISPR therapies for a new era of genomic medicine
The first approval of a CRISPR therapy is expected in 2023. A large number of new gene editing technologies were developed in recent years. Many of these are mechanistically different from the classic “genetic scissors”. This talk will be about the current state of CRISPR technology development and clinical translation.

.